Adjuvant therapy in non-small cell lung cancer: is targeted therapy joining the standard of care?

References

• Bradbury P, Sivajohanathan D, Chan A, et al. Postoperative adjuvant systemic therapy in completely resected non-small-cell lung cancer: a systematic review. Clin Lung Cancer. 2017 May;18(3):259–273.e8. Epub 2016 Jul 12. PMID: 2816294.
   PubMed Web of Science ®Google Scholar
• Lopez-Chavez A, Thomas A, Evbuomwan MO, et al. EGFR mutations in Latinos from the United States and Latin America. J Glob Oncol. 2016 Mar 9;2(5):259–267. PMID: 28717712; PMCID: PMC5493261.
   PubMedGoogle Scholar
• Greenhalgh J, Boland A, Bates V, et al. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer. Cochrane Database Syst Rev. 2021 Mar;18(3):CD010383. PMID: 33734432.
   PubMedGoogle Scholar
• Mok TS, Wu Y-L, Ahn M-J, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med. 2017 Feb 16;376(7):629–640. Epub 2016 Dec 6. PMID: 27959700; PMCID: PMC6762027.
   PubMed Web of Science ®Google Scholar
• Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018 Jan 11;378(2):113–125. Epub 2017 Nov 18. PMID: 29151359.
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020 Jan 2;382(1):41–50. Epub 2019 Nov 21. PMID: 31751012.
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Fossati R, Torri V, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer. J Natl Cancer Inst. 2003 Oct 1;95(19):1453–1461. PMID: 14519751.
   PubMed Web of Science ®Google Scholar
• Waller D, Peake MD, Stephens RJ, et al. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the big lung trial. Eur J Cardiothorac Surg. 2004 Jul;26(1):173–182. PMID: 15200998.
   PubMed Web of Science ®Google Scholar
• Rotolo F, Dunant A, Le Chevalier T, et al. Adjuvant cisplatin-based chemotherapy in nonsmall-cell lung cancer: new insights into the effect on failure type via a multistate approach. Ann Oncol. 2014 Nov;25(11):2162–2166. Epub 2014 Sep 5. PMID: 25193990.
   PubMed Web of Science ®Google Scholar
• Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005 Jun 23;352(25):2589–2597. PMID: 15972865.
   PubMed Web of Science ®Google Scholar
• Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (adjuvant navelbine international trialist association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006 Sep 7;7(9):719–727. Erratum in: Lancet Oncol. 2006 Oct;7(10):797.PMID: 16945766.
   PubMed Web of Science ®Google Scholar
• Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group. J Clin Oncol. 2008 Jul 20;26(21):3552–3559. Epub 2008 May 27. PMID: 18506026.
   PubMed Web of Science ®Google Scholar
• Arriagada R, Auperin A, Burdett S, et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet. 2010 Apr 10;375(9722):1267–1277. Epub 2010 Mar 24. PMID: 20338627; PMCID: PMC2853682.
   PubMed Web of Science ®Google Scholar
• Strauss GM, Herndon JE 2nd, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the cancer and leukemia group B, radiation therapy oncology group, and north central cancer treatment group study groups. J Clin Oncol. 2008 Nov 1;26(31):5043–5051. Epub 2008 Sep 22. PMID: 18809614; PMCID: PMC2652093.
   PubMed Web of Science ®Google Scholar
• Schmid-Bindert G, Engel-Riedel W, Reck M, et al. A randomized phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB or II non-small-cell lung cancer. Lung Cancer. 2015 Dec;90(3):397–404. Epub 2015 Nov 7. PMID: 26791798.
   PubMed Web of Science ®Google Scholar
• Kreuter M, Vansteenkiste J, Fischer JR, et al. Three-year follow-up of a randomized phase II trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine (the TREAT study). J Thorac Oncol. 2016 Jan;11(1):85–93. PMID: 26762743.
   PubMed Web of Science ®Google Scholar
• Kenmotsu H, Yamamoto N, Yamanaka T, et al. Randomized phase III study of pemetrexed plus cisplatin versus vinorelbine plus cisplatin for completely resected stage II to IIIA nonsquamous non-small-cell lung cancer. J Clin Oncol. 2020 Jul 1;38(19):2187–2196. Epub 2020 May 14. PMID: 32407216.
   PubMed Web of Science ®Google Scholar
• Booth CM, Shepherd FA, Peng Y, et al. Time to adjuvant chemotherapy and survival in non-small cell lung cancer: a population-based study. Cancer. 2013 Mar 15;119(6):1243–1250. Epub 2012 Nov 6. PMID: 23131995.
   PubMed Web of Science ®Google Scholar
• Salazar MC, Rosen JE, Wang Z, et al. Association of delayed adjuvant chemotherapy with survival after lung cancer surgery. JAMA Oncol. 2017 May 1;3(5):610–619. PMID: 28056112; PMCID: PMC5824207.
   PubMed Web of Science ®Google Scholar
• Pathak R, Goldberg SB, Canavan M, et al. Association of survival with adjuvant chemotherapy among patients with early-stage non-small cell lung Cancer with vs without high-risk clinicopathologic features. JAMA Oncol. 2020 Sep 17;6(11):1–10. Epub ahead of print. PMID: 32940636; PMCID: PMC7499246.
   Web of Science ®Google Scholar
• Chaudhuri AA, Chabon JJ, Lovejoy AF, et al. Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling. Cancer Discov. 2017 Dec 7;7(12):1394–1403. Epub 2017 Sep 24. PMID: 28899864; PMCID: PMC5895851.
   PubMed Web of Science ®Google Scholar
• AbdulJabbar K, Raza SEA, Rosenthal R, et al. TRACERx consortium, Swanton C, Yuan Y. Geospatial immune variability illuminates differential evolution of lung adenocarcinoma. Nat Med. 2020 Jul;26(7):1054–1062. Epub 2020 May 27. PMID: 32461698.
   PubMed Web of Science ®Google Scholar
• Pennell NA, Neal JW, Chaft JE, et al. SELECT: a phase II trial of adjuvant erlotinib in patients with resected epidermal growth factor receptor-mutant non-small-cell lung cancer. J Clin Oncol. 2019 Jan 10;37(2):97–104. Epub 2018 Nov 16. Erratum in: J Clin Oncol. 2019 Mar 1;37(7):612. PMID: 30444685; PMCID: PMC6524649.
   PubMed Web of Science ®Google Scholar
• Yue D, Xu S, Wang Q, et al. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial. Lancet Respir Med. 2018 Nov 6;6(11):863–873. Epub 2018 Aug 24. PMID: 30150014.
   PubMed Web of Science ®Google Scholar
• Sands J, Mandrekar SJ, Oxnard GR, et al. ALCHEMIST: adjuvant targeted therapy or immunotherapy for high-risk resected NSCLC. J Clin Oncol. 2020;38(15_suppl): TPS9077–TPS9077.
   Web of Science ®Google Scholar
• Zhong WZ, Wang Q, Mao WM, et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC: final overall survival analysis of CTONG1104 phase III trial. J Clin Oncol. 2021 Mar 1;39(7):713–722. Epub 2020 Dec 17. PMID: 33332190.
   PubMed Web of Science ®Google Scholar
• Zhou C, et al. FP14.11 icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant NSCLC (EVIDENCE): a randomized, open-label, phase 3 study. J Thorac Oncol. 2021;16(3):S232.
   Web of Science ®Google Scholar
• Wu YL, Tsuboi M, He J, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2020 Oct 29;383(18):1711–1723. Epub 2020 Sep 19. PMID: 32955177.
   PubMed Web of Science ®Google Scholar
• Tsuboi M, Wu YL, He J. et al. Osimertinib adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) NSCLC (ADAURA): central nervous system (CNS) disease recurrence. Ann Oncol. 2020;31(S6).
   Google Scholar
• Mauguen A, Pignon JP, Burdett S, et al. Surrogate lung project collaborative group. Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients’ data. Lancet Oncol. 2013 Jun 14;14(7):619–626. Epub 2013 May 14. PMID: 23680111; PMCID: PMC3732017.
   PubMed Web of Science ®Google Scholar
• Smeltzer MP, Wynes MW, Lantuejoul S, et al. The international association for the study of lung cancer global survey on molecular testing in lung cancer. J Thorac Oncol. 2020 Sep;15(9):1434–1448. Epub 2020 May 20. PMID: 32445813.
   PubMed Web of Science ®Google Scholar